Zydus receives USFDA approval for its first transdermal product, Rivastigmine Transdermal System

Deepthi | Myequity news | Date : 05-03-2019 13:05:00 IST

Zydus Cadila
has received the approval from the USFDA to market Rivastigmine Transdermal System (USRLD EXELON® PATCH), 4.6mg/24hrs, 9.5mg/24hrs and 13.3mg/24hrs, marking its first approval for a transdermal product in the US. It is indicated for the treatment of dementia (memory loss) associated with Alzheimer’s and Parkinson’s diseases.

The group also received the final approval for Rosuvastatin Tablets USP (USRLD—Crestor) in the strengths of 5mg, 10mg, 20mg, and 40mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

More from Myequity